• 17 April 2018

    Azeliragon: The third Alzheimer’s failure of 2018

    After the termination of Takeda’s pioglitazone and Merck & Co.’s verubecestat, vTv Therapeutic’s azeliragon is now the third pipeline drug to fail clinical trials for Alzheimer’s disease (AD) this year.